Monday, January 29, 2018

TherapeuticsMD (TXMD): Hidden Opportunity In FDA Compounding ... hours ago
That outbreak, along with other FDA concerns about compounded drugs, emphasized the need for better control of compounding practices and oversight of compounding pharmacies. W e see TX-001HR, as potentially the first and only bio-identical FDA-approved combination of 17 β-estradiol and progesterone, as uniquely ...

No comments: